Markets
ED

Close Update: Stocks Fall to Pare Week's Gains as Oil Retreats

Stocks pulled back on Thursday, trimming a week of gains as oil futures fell and a mixed slate of economic data didn't offer any clear direction ahead of next week's Federal Reserve interest-rate meeting.

Verizon ( VZ ) led declines on the blue-chip Dow Jones Industrial Average after reporting revenue that fell short of expectations. That dragged down the S&P 500's telecommunications services sector, which posted a 2.9% fall near the close.

US oil futures were trading down about 1.4% late in the day to $43.58 a barrel, pulling down the S&P 500's energy sector, which slipped 0.4%. The utilities group was down 2.2% and consumer staples fell 1.6%. Health care stocks were the lone gainers, rising 0.5%.

In economic data, Initial unemployment claims fell to a 42-year low of 247,000 last week but the Philadelphia Fed business outlook index fell to negative 1.6 reading in April from positive 12.4 in March, missing expectations for a small decline to a positive 9 reading.

Housing prices improved slightly while the Chicago Fed national activity index contracted to negative 0.44 in March from a downward revised negative 0.38 the prior month.

The Federal Open Market Committee meets from April 26 to 27.

Here's where the markets stood at the close:

US MARKETS

Dow Jones Industrial Average was down 113.75 points (-0.63%)

S&P 500 was down 10.92 points (-0.52%)

Nasdaq Composite Index was down 2.24 points (-0.05%)

GLOBAL SENTIMENT

FTSE 100 was down 0.45%

Nikkei 225 was up 2.7%

Hang Seng Index was up 1.82%

Shanghai China Composite Index was down 0.66%

UPSIDE MOVERS

(+) CEQP (+42.1%) Forms strategic joint venture with ConEdison ( ED ) to develop existing assets

(+) NOW (+14.07%) Reported better-than-expected Q1 EPS and revenue

(+) VIA (+11.84%) Announces deal with DISH Network

(+) UA (+6.78%) Q1 results beat Wall Street expectations, raised FY16 outlook

DOWNSIDE MOVERS

(-) TRXC (-52.32%) Surgical system denied fast FDA clearance

(-) SRPT (-44.09%) Negative FDA clinical review of Duchenne muscular dystrophy drug eteplirsen

(-) NGVC (-32.83%) Preliminary Q2 results below Wall Street expectations

(-) TBI (-22.8%) Reported better-than-expected Q1 EPS, on below consensus revenue, guides Q2 and FY16 below street estimates

(-) UAL (-9.98%) Projects decline in Q2 passenger revenue

(-) VZ (-3.34%) Q1 revenues miss, Q2 earnings pressure seen

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ED CEQP VZ NOW

Other Topics

Stocks

Latest Markets Videos